How large was the net share change from the EW insider’s June 30, 2026 transactions?

The net effect was a disposition of 619 shares on a buy-sell basis. He exercised stock options for 619 shares and sold 619 shares, with the transaction summary showing netBuySellShares of -619, indicating a small net reduction in directly held shares.

Edwards Lifesciences (NYSE: EW) exec sells 619 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised and sold a small block of shares under a pre-planned program. He exercised employee stock options to acquire 619 shares of common stock at $72.68 per share, then sold 619 shares in an open-market sale at a weighted average price of $91.4002 per share.

The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026, indicating they were pre-scheduled. After these trades, Lippis directly holds about 40,410.9103 shares of common stock and 5,571 employee stock options.

Insider Trade Summary 10b5-1

Net Seller: 619 shares ($56,577)

Net Sell 3 txns

Insider Lippis Daniel J.

Role CVP, TAVR

Sold 619 shs ($57K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	619	$0.00	--
Exercise	Common Stock	619	$72.68	$45K
Sale	Common Stock	619	$91.4002	$57K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 5,571 shares (Direct, null); Common Stock — 41,029.91 shares (Direct, null)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This transaction was executed in multiple trades at prices ranging from $91.185 to $91.650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 619 shares Sale price: $91.4002 per share Option exercise shares: 619 shares +5 more

8 metrics

Shares sold 619 shares Open-market sale on June 30, 2026

Sale price $91.4002 per share Weighted average sale price

Option exercise shares 619 shares Employee stock option exercise on June 30, 2026

Option exercise price $72.68 per share Employee Stock Option (Right to Acquire)

Common shares held after 40,410.9103 shares Direct common stock holdings post-transaction

Options remaining 5,571 options Employee stock options after exercise

10b5-1 plan adoption date February 13, 2026 Plan governing these trades

Option expiration May 6, 2027 Expiration date of exercised option grant

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (Right to Acquire), open-market sale, derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (Right to Acquire) financial

"security_title": "Employee Stock Option (Right to Acquire)""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 08:01 PM Accepted by SEC EDGAR 06/30/2026 - 08:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last)

(First)

(Middle)

ONE EDWARDS WAY

(Street)

IRVINE

CALIFORNIA

92614

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CVP, TAVR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		M⁽¹⁾		619	A	$72.68	41,029.9103	D
Common Stock	06/30/2026		S⁽¹⁾		619	D	$91.4002⁽²⁾	40,410.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Acquire)	$72.68	06/30/2026		M			619	05/07/2021	05/06/2027	Common Stock	619	$0.0000	5,571	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

2. This transaction was executed in multiple trades at prices ranging from $91.185 to $91.650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did EW executive Daniel J. Lippis report?

Daniel J. Lippis reported exercising employee stock options for 619 Edwards Lifesciences shares at $72.68 each and selling 619 shares in an open-market transaction at a weighted average of $91.4002 per share, all on June 30, 2026.

Was the Edwards Lifesciences (EW) insider sale part of a 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Daniel J. Lippis on February 13, 2026. Such plans pre-schedule trades, making their timing more routine and less reflective of short-term views.

How many Edwards Lifesciences (EW) shares does Daniel J. Lippis hold after these trades?

Following the reported transactions, Daniel J. Lippis directly holds 40,410.9103 shares of Edwards Lifesciences common stock. This figure reflects his remaining equity position after exercising 619 options and selling 619 shares on June 30, 2026.

What stock options does the EW executive still retain after exercising 619 options?

After exercising 619 employee stock options, Daniel J. Lippis retains 5,571 options. These options carry a conversion or exercise price of $72.68 per share and are scheduled to expire on May 6, 2027, according to the Form 4 details.

What prices were involved in the Edwards Lifesciences (EW) insider trades?

The option exercise price was $72.68 per share, while the sale transaction’s weighted average price was $91.4002 per share. Individual sale trades occurred in a range between $91.185 and $91.650, based on the filing footnote.